Drug delivery systems and in vivo efficacy of the serine protease inhibitor UAMC-00050 in a preclinical model for irritable bowel syndrome. University of Antwerp
Laboratory of Pharmaceutical Technology and Biopharmacy, Medicinal Chemistry (UAMC), Laboratory Experimental Medicine and Pediatrics (LEMP)
The serine protease inhibitor UAMC-00050, previously shown efficacious in 2 preclinical IBS models after systemic administration, will be formulated for oral and rectal administration. The drug delivery systems will be tested in the rat IBS model for dose determination, efficacy, time of administration and serum concentrations, a crucial step towards further valorization of the compound.